ULTRAGENYX PHARMACEUTICAL IN (RARE) Earnings History & Surprises
NASDAQ:RARE • US90400D1081
22.61 USD
+1.36 (+6.4%)
At close: Mar 9, 2026
22.61 USD
0 (0%)
After Hours: 3/9/2026, 8:00:02 PM
Past quarterly earnings results for ULTRAGENYX PHARMACEUTICAL IN (RARE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$1.51
Revenue Estimate167.31M
Last Reported
Release DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported-$1.29
EPS Surprise -15.82%
Revenue Surprise 3.03%
Beat Rate
56%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.29 | -1.11 | -15.82% | 7.19% | 207M | 200.91M | 3.03% | 25.55% |
| Q3 2025 | -1.81 | -1.26 | -43.75% | -29.29% | 159.933M | 170.04M | -5.94% | 14.65% |
| Q2 2025 | -1.17 | -1.32 | 11.68% | 23.03% | 166.496M | 164.82M | 1.02% | 13.24% |
| Q1 2025 | -1.57 | -1.65 | 4.60% | 22.66% | 139.292M | 146.7M | -5.05% | 27.99% |
| Q4 2024 | -1.39 | -1.32 | -5.63% | 8.55% | 164.877M | 158.5M | 4.02% | 29.42% |
| Q3 2024 | -1.40 | -1.48 | 5.37% | 37.22% | 139.494M | 138.51M | 0.71% | 42.27% |
| Q2 2024 | -1.52 | -1.73 | 12.01% | 32.44% | 147.026M | 125.64M | 17.02% | 35.75% |
| Q1 2024 | -2.03 | -1.77 | -14.94% | 12.88% | 108.833M | 118.33M | -8.03% | 8.30% |
| Q4 2023 | -1.52 | -1.65 | 7.99% | 29.63% | 127.392M | 121.77M | 4.62% | 23.32% |
| Q3 2023 | -2.23 | -2.12 | -5.20% | 36.29% | 98.052M | 111.82M | -12.31% | 8.11% |
| Q2 2023 | -2.25 | -2.12 | -6.35% | 0.44% | 108.309M | 106.9M | 1.32% | 21.29% |
| Q1 2023 | -2.33 | -2.02 | -15.58% | -6.39% | 100.496M | 106.78M | -5.88% | 25.78% |
| Q4 2022 | -2.16 | -2.18 | 1.14% | -20.67% | 103.3M | 107.22M | -3.66% | 23.86% |
| Q3 2022 | -3.50 | -1.85 | -89.21% | -224.07% | 90.7M | 98.121M | -7.56% | 11.15% |
| Q2 2022 | -2.26 | -1.79 | -26.47% | -24.86% | 89.3M | 89.265M | 0.04% | 2.64% |
| Q1 2022 | -2.19 | -1.80 | -21.97% | -7.88% | 79.9M | 85.327M | -6.36% | -19.62% |
| Q4 2021 | -1.79 | -1.37 | -30.74% | -383.78% | 83.4M | 85.471M | -2.42% | -8.85% |
| Q3 2021 | -1.08 | -1.44 | 24.80% | 4.42% | 81.6M | 83.178M | -1.90% | 0.12% |
| Q2 2021 | -1.81 | -1.36 | -33.07% | -541.46% | 87M | 87.6M | -0.68% | 41.00% |
| Q1 2021 | -2.03 | -1.26 | -60.89% | -6.28% | 99.4M | 78.58M | 26.50% | 173.83% |
| Q4 2020 | -0.37 | -1.18 | 68.76% | - | 91.5M | 71.955M | 27.16% | - |
| Q3 2020 | -1.13 | -1.28 | 11.98% | - | 81.5M | 56.107M | 45.26% | - |
| Q2 2020 | 0.41 | -1.57 | 126.03% | - | 61.7M | 39.901M | 54.63% | - |
| Q1 2020 | -1.91 | -1.72 | -11.34% | - | 36.3M | 37.477M | -3.14% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-10.82%
Max EPS beat (4)
11.68%
Min EPS beat (4)
-43.75%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-1.74%
Max Revenue beat (4)
3.03%
Min Revenue beat (4)
-5.94%
Analysis
In the last 4 quarters, RARE has beaten EPS estimates in 2 out of 4 releases
RARE has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, RARE reported -10.8% below the EPS estimates on average.
In the last 4 quarters, RARE reported -1.7% below the revenue estimates on average.
ULTRAGENYX PHARMACEUTICAL IN / RARE Earnings FAQ
When did ULTRAGENYX PHARMACEUTICAL IN (RARE) report earnings last quarter?
ULTRAGENYX PHARMACEUTICAL IN (RARE) last reported earnings on 2/12/2026.
Can you provide information on whether ULTRAGENYX PHARMACEUTICAL IN beat earnings estimates in the last quarter?
ULTRAGENYX PHARMACEUTICAL IN (RARE) missed EPS estimates and beat revenue estimates in the most recent quarter.
How often does ULTRAGENYX PHARMACEUTICAL IN (RARE) beat earnings estimates?
In the last 4 quarters, ULTRAGENYX PHARMACEUTICAL IN (RARE) has beaten EPS estimates in 2 out of 4 releases.